Introduction
Apoptosis (programmed cell death) is an intrinsic cell death program that is highly conserved throughout evolution and involved in the regulation of various basic physiological processes both during development and in the adult organism. 1 Given the crucial role of cell death in the maintenance of tissue homeostasis, evasion of apoptosis is one of the hallmarks of human cancers. 2 Proper regulation of programmed cell death might be relevant especially in cellular compartments with a high cell turnover and intrinsic proliferative capacity, such as the hematopoietic system. 3, 4 It follows that too little apoptosis coupled with malignant transformation may result in the development of leukemia and lymphoma. 3, 4 Oncogenic mutations that block apoptosis may promote tumor initiation and progression by creating a permissive environment for genetic instability and accumulation of gene mutations, by imposing resistance to immune-based destruction and by facilitating growth factor-independent survival as well as anchorageindependent growth during metastasis. 2, 5 By comparison, some oncogenic events that can promote apoptosis, such as the myc oncogene, may cause a selective pressure on cancer cells to escape apoptosis in the multistep process of carcinogenesis. 6 In addition, most cytotoxic therapies that are used at present in clinical practice, such as chemotherapy, g-irradiation, suicide genes or immunotherapy, have been reported to act by inducing cell death in tumor cells. 7, 8 As the same oncogenic alterations and defects in cell death pathways during tumorigenesis can also confer treatment resistance, 5 apoptosis provides a conceptual framework to link cancer formation and cancer therapy.
The core apoptotic machinery
Activation of caspases, a family of cysteine proteases that act as death effector molecules, is a common event during most forms of apoptotic cell death ( Figure 1) . 9 There are two major apoptosis signaling pathways that can lead to caspase activation, that is, the death receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway. In the death receptor pathway, stimulation of death receptors of the tumor necrosis factor receptor superfamily, such as CD95, or TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptors by their respective ligands or agonistic antibodies causes receptor aggregation followed by the recruitment of the adaptor molecule Fas-associated death domain and caspase-8 to form the deathinducing signaling complex. 10, 11 Upon recruitment to activated death receptors, caspase-8 becomes activated and can transmit the apoptotic signal either by directly cleaving downstream effector caspases or by proteolytic processing of Bid. Truncated Bid then translocates to mitochondria to engage the mitochondrial pathway. In the mitochondrial pathway, which can be engaged by a variety of upstream stimuli, apoptogenic factors are released from the mitochondrial intermembrane space into the cytosol, including cytochrome c, apoptosis-inducing factor, second mitochondria-derived activator of caspase (Smac)/direct inhibitor of apoptosis (IAP)-binding protein with low PI (DIABLO) or Omi/high-temperature requirement protein A2 (HtrA2). 12 The release of cytochrome c into the cytosol promotes activation of caspases through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex. 13 Smac/DIABLO facilitates caspase activation by neutralizing IAPs that inhibit caspase-3, -7 and -9.
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IAP proteins: structure and function
Inhibitors of apoptosis (IAP) proteins are endogenous caspase inhibitors that are highly conserved throughout evolution from Drosophila to vertebrates. 16, 17 This protein family consists of eight human analogs, that is, neuronal apoptosis inhibitory protein (NAIP/BIRC1/NLRB), cellular IAP1 (cIAP1)/human IAP2/ BIRC2, cellular IAP2 (cIAP2)/human IAP1/BIRC3, X-linked IAP (XIAP)/BIRC4, survivin/BIRC5, baculoviral IAP repeat (BIR)-containing ubiquitin-conjugating enzyme/apollon/BIRC6, livin/ melanoma-IAP (ML-IAP)/BIRC7/KIAP and testis-specific IAP (Ts-IAP)/hILP-2/BIRC8 (Table 1) . 16, 17 All IAPs contain at least one BIR domain, which is required for their classification as IAP protein (Figure 2 ). The BIR domain is a 70-to 80-amino-acidlong motif that relates to the initial discovery of these proteins in baculovirus as indicated by the name. 17 Human IAP proteins harbor at least one and up to three copies of the BIR domain.
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In addition to the BIR motif, all IAP proteins except survivin harbor one or more of the other functional domains, that is, the really interesting new gene (RING) domain and the caspase activating and recruitment domain (CARD). 17 The RING domain possesses E3 ubiquitin ligase activity and mediates the ubiquitination and proteasomal degradation of substrates. 18 IAP proteins with a RING domain can mediate their auto-or heteroubiquitination in a regulatory loop or degrade other substrates, for example, caspases and Smac. 18 The CARD is a protein-protein interaction domain that mediates oligomerization with other CARD-containing proteins and is found in a number of proteins involved in the regulation of cell death. 19 Among the mammalian IAP proteins, XIAP possesses the most potent antiapoptotic properties. 20 XIAP contains three BIR domains and a C-terminal RING motif. 17 The second and third BIR domains of XIAP mediate inhibition of caspase-3/-7 and caspase-9, respectively, through distinct mechanisms. 21 The linker segment that precedes the BIR2 domain binds to the active site of effector caspase-3 or -7 and prevents substrate binding and subsequent catalysis, whereas the BIR2 domain interacts with the N terminus of the caspase small subunit. [22] [23] [24] The BIR3 domain of XIAP sequesters active caspase-9 in a monomeric state through two separate interaction sites. 25, 26 A surface groove on the BIR3 domain of XIAP binds to the IAP-binding motif (IBM) on the N terminus of the small subunit of caspase-9, which is exposed upon proteolytic processing of caspase-9, whereas a distinct part of XIAP-BIR3 heterodimerizes with an interface of caspase-9, which is required for homodimerization of caspase-9. 25, 26 In addition to its role as an inhibitor of effector caspases, XIAP can also negatively regulate apoptosis through the E3 ligase activity of its RING domain that mediates proteasomal degradation of proapoptotic proteins, for example, caspases. 18 Furthermore, XIAP has been shown to promote nuclear factor k-B (NF-kB) activation by enhancing the translocation of NF-kB from the cytoplasm into the nucleus, by increasing the degradation of inhibitor kB protein and through its association with TAK1 kinase and its cofactor TAB1. [27] [28] [29] [30] [31] In contrast to XIAP, the antiapoptotic activity of cIAP1 and cIAP2 is considered not to be primarily related to direct inhibition of caspases. Although cIAP1 and cIAP2 can bind to caspases, the BIR domains of cIAPs are unable to inhibit caspases because they lack the critical residues that mediate caspase inhibition in XIAP. 20 Rather, they interfere with caspase activation by targeting caspases for proteasomal degradation through their RING domain. 32 Moreover, cIAP1 and cIAP2 were recently reported to support survival by promoting activation of the canonical NF-kB cascade. To this end, cIAP1 and cIAP2 were identified as E3 ligases that cause K63 polyubiquitination of receptor interacting protein 1 (RIP1). [33] [34] [35] K63 polyubiquitination is a post-transcriptional modification that modulates signaling properties rather than initiating proteasomal degradation. 36 Accordingly, K63 polyubiquitination of RIP1 promotes its bindings to TAK1 and to I-kappa B kinase g (IKKg)/NF-kB essential modulator (NEMO), thereby leading to NF-kB activation. Moreover, cIAP1 has been described to exert its oncogenic Livin/ML-IAP contains a single BIR domain at the N terminus as well as a C-terminal RING domain and is located on the long arm of chromosome 20 at 20q13.3. 38, 39 Two splice variants have been identified, that is, livin a, which harbors an additional 18 amino acid stretch at the BIR-RING linker region, and livin b. 40 The functional difference between these splice variants is uncertain at present because some conflicting data exist. 41 Livin blocks apoptosis by binding and inhibiting caspases and by serving as a sink for Smac. 39, 42, 43 In addition, the antiapoptotic function of livin has been linked with its ability to stimulate TAK1-dependent JNK1 activation. 44 Interestingly, livin can be converted from an antiapoptotic factor to a proapoptotic killer by caspase-mediated cleavage. 45 In addition, the subcellular localization of livin may determine the balance between its antiand proapoptotic activities, as a perinuclear localization of truncated livin has been reported to be essential for its proapoptotic function. 46 Survivin contains a single BIR domain only and is the smallest mammalian member of the IAP family. 47 The survivin gene, which is located on chromosome 17q25 in humans, gives rise to five alternatively spliced survivin transcripts, that is, wild-type survivin, survivin-2a, survivin-2B, survivin-DEx-3 and survivin-3B. 47 The expression of survivin is regulated in a cell-cycledependent manner with highest levels in mitosis, which is largely controlled at the level of gene transcription. 47 In addition, survivin protein stability is controlled by phosphorylation of survivin on Thr34 by a p34cdc2-cyclin B1 complex during mitosis. 48, 49 Survivin is involved in both the control of cell proliferation and cell death. 47 The antiapoptotic function of survivin has been linked with its interaction with Smac/DIABLO, to the stabilization of XIAP protein through its binding to XIAP and to inhibition of mitochondrial and apoptosis-inducing factor-dependent apoptotic pathways.
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IAPs and their endogenous antagonists
The antiapoptotic activity of IAPs is held in check upon induction of apoptosis by several endogenous inhibitors, including Smac/DIABLO, Omi/HtrA2 and XIAP-associated factor 1 (XAF1), to ensure that cell death proceeds.
Smac/DIABLO
Smac and its murine homolog DIABLO are nuclear encoded mitochondrial proteins, which are imported into the mitochondrial intermembrane space via a mitochondrial localization signal that is removed upon uptake into the mitochondrion by proteolytic cleavage to generate the mature 23 kDa protein. 14, 15 Only upon removal of the mitochondrial localization signal the IBM is exposed at the N-terminus of Smac/DIABLO 14 ( Table 2) . Interestingly, the AVPI-like sequence of the IBM is conserved in Drosophila IBM-containing proteins, e.g. Reaper, Grim and Hid. 21 Structural studies demonstrated that Smac/DIABLO acts as homodimer with the IBM present in a bivalent configuration and binds to IAPs in a BIR-dependent way. 53, 54 Accordingly, one Smac/DIABLO dimer binds one XIAP molecule with one IAP-binding motif interacting with BIR2 and the other one binding to BIR3 (Figure 3) . 55 Intriguingly, the same surface groove on the BIR3 domain of XIAP, which binds to the IAPbinding motif (IBM) of the N-terminus of Smac also binds to the IBM exposed at the N-terminus of the small subunit of caspase-9 following the autocatalytic processing of caspase-9. 25, 26 This structural homology allows Smac/DIABLO to displace caspase-9 from XIAP and to promote caspase activation and apoptosis. 25 
Omi/HtrA2
As a nuclear-encoded protein Omi/HtrA2 is translated in the cytosol and then imported into the mitochondrial intermembrane space via a mitochondrial localization signal. [56] [57] [58] [59] Cleavage of Omi/HtrA2 in the intermembrane space produces the 37 kDa mature form that contains an IBM at its N-terminus 56 ( Table 2) . Upon the induction of apoptosis Omi/HtrA2 is released from mitochondria into the cytosol where it promotes cell death in a caspase-dependent way by binding to and neutralizing IAPs via its N-terminal IAP-binding motif, and also in a caspase-independent way by virtue of its protease activity. 56, 60 In addition, Omi/HtrA2 plays an important physiological role in the regulation of mitochondrial homeostasis.
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XAF1
XIAP-associated factor 1 is a nuclear protein that acts as an endogenous antagonist of XIAP and consists of seven zinc-finger domains. 61, 62 Thus, in healthy cells, XAF1 is separated from its target by virtue of its subcellular localization in the nucleus. In contrast to Smac/DIABLO and Omi/HtrA2, XAF1 is constitutively able to interact with and inhibit XIAP, and thus does not need to be proteolytically processed into an active form. 61 In biochemical studies, XAF1 binds and sequesters XIAP in the nucleus, thereby preventing XIAP from inhibiting caspases in the cytosol. 61 However, the exact interacting domains that mediate the interaction of XIAP and XAF1 have not yet been identified. 61 Furthermore, XAF1 has been reported to bind to XIAP, cIAP1, cIAP2, livin, ILP2 and NAIP, but not survivin; however, it promotes the degradation of survivin indirectly through a 
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XAF1-XIAP complex. 63 Expression levels of XAF1 are positively regulated by type I interferons, especially interferon-b, demonstrating that XAF1 is an interferon-stimulated gene. 64 
Role of IAPs and IAP antagonists in hematological malignancies
Expression and/or function of IAP proteins are deregulated in many human cancers, including hematological disorders, for example, because of an increase in mRNA or protein expression or loss of endogenous inhibitors, such as Smac/DIABLO or XAF1. In a number of retrospective trials, the expression of IAPs and their antagonists have been correlated to clinical parameters and prognosis as discussed in the following paragraphs (Table 3) .
XIAP and cIAPs in hematological malignancies
Chromosomal translocations are a common cause of abnormal gene expression in leukemia and lymphoma, and thus also present one mechanism that can result in abnormal levels of IAPs. For example, the t(11;18)(q21;q21) translocation affects the cIAP2 gene in a large proportion of MALT (mucosaassociated lymphoid tissue) lymphoma. [75] [76] [77] This translocation fuses the BIR domains of cIAP2 with the MALT1 protein, a paracaspase and critical mediator of T-cell receptor-triggered NF-kB activation. Interestingly, recent evidence suggests that the cIAP2-MALT1 fusion protein constitutively activates the NF-kB pathway independently of signaling adaptors that otherwise regulate its activity, such as TRAF proteins. 78 Furthermore, upregulation of cIAP2 was found to be a consistent phenotype of human T-cell leukemia virus type 1-transformed adult T-cell leukemia (ATL). 79 In ATL, cIAP2 upregulation was mediated through NF-kB activation, which was triggered by the human T-cell leukemia virus type 1-encoded viral oncoprotein Tax. 79 RNA interference studies showed that the enhanced cIAP2 levels were critical for the survival of human T-cell leukemia virus type 1-transformed lymphocytes. 79 Recently, inactivating mutations in cIAP1 or cIAP2 were identified in multiple myeloma that result in constitutive activation of the noncanonical NF-kB pathway through accumulation of NF-kB-inducing kinase, as cIAP1 and cIAP2 were shown to function as E3 ligases for NF-kB-inducing kinase. 80, 81 Moreover, elevated cIAP2 were detected in mature neutrophils from a patient with chronic neutrophilic leukemia, indicating that cIAP2-mediated antiapoptotic events may contribute to neutrophilia. 82 In line with the notion that cIAP2 is part of a survival program in human neutrophils, expression of cIAP2 was reported to be selectively upregulated by stimulation with granulocyte colony-stimulating factor, but not with granulocyte-macrophage colony-stimulating factor. 82 This granulocyte colony-stimulating factor-stimulated upregulation of cIAP2 was mediated through the Janus kinase 2/signal transducer and activator of transcription 3-dependent pathway. 82 Also, there is recent evidence that cIAP1 is involved in the regulation of differentiation in monocytes. To this end, cIAP1 was reported to translocate from the nucleus to the Golgi in monocytic cell lines and human monocytes that undergo differentiation. 83 This nucleocytoplasmic redistribution of cIAP1 was mediated through a nuclear export signal-and leptomycin B-sensitive mechanism. 83 Recently, the b-isoform of HSP90 was shown to function as a chaperone toward cIAP1, preventing its auto-ubiquitination and degradation in the cytosol during cellular differentiation. 84 Accordingly, inhibition of HSP90 proteins by small chemical molecules and specific depletion of the HSP90 b-isoform by siRNA resulted in auto-ubiquitination of cIAP1, its degradation by the proteasome machinery and inhibition of differentiation. 84 The question whether or not an abnormal subcellular localization of cIAP1 contributes to the differentiation defects in some hematological malignancies remains to be addressed in future studies.
Furthermore, gene expression profiling of IAP genes in hematological malignancies unraveled a specific pattern of expression of cIAP1, cIAP2 and survivin in chronic lymphocytic leukemia (CLL), B-cell acute lymphocytic leukemia and follicular lymphoma samples that discriminated these diseases from each other and from other entities. 85 In CLL cells that were resistant to irradiation-induced apoptosis, cIAP1 was identified in gene expression profiling studies as one of the genes that was upregulated in resistant compared with sensitive samples. 86 By comparison, immunocytochemical analysis expression levels of cIAP1, cIAP2 and XIAP in CLL patients revealed no correlation between the levels of IAPs expression and prognostic factors or sensitivity to fludarabine-induced apoptosis. 87 In adult acute mixed lineage leukemia, higher expression levels of XIAP, survivin and NAIP were detected compared with ALL, indicating that higher levels of several IAPs may contribute to the chemotherapy-resistant nature of this type of leukemia. 88 Although it was reported in one study that acute myeloid leukemia (AML) patients with lower XIAP protein levels have a significantly better survival, 89 another study showed no prognostic impact of XIAP expression in this malignancy. 90 In adult de novo AML, expression levels of XIAP but not other IAP family members were described to correlate with poor prognosis, less favorable cytogenetics and monocytic differentiation; however, no prognostic value was found for survivin in that study. 91 In childhood de novo AML, high expression levels of XIAP and survivin correlated with poor overall survival and an immature M0/1 subtype according to the French-American-British morphology. 
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Survivin in hematological malignancies
Survivin was identified as the fourth most common transcriptome of the human genome in human cancers in a large gene profiling effort. 93 In contrast to its high expression levels in the majority of cancers, survivin was found to be expressed at low or undetectable levels in many normal adult tissues, indicating that survivin facilitates malignant progression of cancer cells. 93 However, survivin is also expressed in certain nonmalignant adult cells, for example, in hematopoietic stem cells, T lymphocytes and vascular endothelial cells. 94 In these cells, survivin promotes proliferation, cytokinesis and survival, pointing to an important role of survivin also in normal physiology. 94 In anaplastic or diffuse large-cell lymphoma or AML, high survivin levels predicted unfavorable prognosis. 89, 95, 96 Interestingly, survivin was recently identified as a target gene of the AML1/ ETO fusion protein in AML carrying the t(8;21)(q22;q22) chromosomal translocation. 97 Ectopic expression of AML1/ETO was shown to stimulate survivin gene expression in both a cell line model and in primary human hematopoietic cells. 97 Transcriptional regulation of survivin by AML1/ETO was further demonstrated by promoter reporter assays and DNA-bindings assays. 97 Functional studies showed that survivin is a critical mediator of AML1/ETO-induced late oncogenic events that promotes proliferation and inhibition of granulocytic differentiation. 97 In pediatric precursor B-cell ALL, overexpression of survivin was found to identify patients with a high risk of early relapse, as higher survivin expression were detected in relapse patients than those with a favorable outcome. 98 Analysis of survivin splice variants in childhood ALL revealed an association between lower expression of survivin-2B, an isoform of survivin with proapoptotic properties, and affiliation to the high-risk group. 99 In multiple myeloma, overexpression of survivin correlated with adverse clinical outcome. 100 Antagonizing survivin by RNA interference-mediated knockdown resulted in growth inhibition of myeloma cells and also enhanced the sensitivity to standard antimyeloma agents. 100 Survivin was found to be overexpressed also in ATL, and survivin mRNA levels were described to be a marker for clinical stages or minimal residual disease. 101, 102 Accordingly, low levels of survivin were detected in chronic-type ATL, low to high levels in acute type and extremely high levels in ATL cell lines. 102 Interestingly, sodium arsenite caused downregulation of survivin at both the mRNA and protein levels, resulting in growth inhibition and apoptosis induction in ATL cells. 101 In Bcr-abl-positive chronic myelogenous leukemia cells, the Bcr-abl oncogene was found to cause an increase in survivin expression. 103 Downregulation of survivin by dominantnegative or antisense survivin potentiated STI571-induced apoptosis in Bcr-abl-positive cells, indicating that survivin is involved in the Bcr-abl-mediated antiapoptotic program in chronic myelogenous leukemia. 103 Stimulation of B-CLL cells with CD40 ligand to mimic the survival signals present in the microenvironment caused upregulation of survivin expression, whereas expression levels of other IAP proteins remained unchanged. 104 Immunohistochemical staining of lymph node and bone marrow biopsies showed high survivin levels in the B-CLL proliferative pool. 104 
Livin in hematological malignancies
Surprisingly, the expression rate of the antiapoptotic protein livin was identified recently as a favorable prognostic factor in childhood ALL. 105 Notably, livin expression rate was high in t(12;21) and very low in t(9;22)/11q23 rearrangements, 105 which have been reported to be associated with the best and worst clinical outcomes, respectively. [106] [107] [108] In this context, it is interesting to note that livin can be converted from an antiapoptotic to a proapoptotic factor by caspase-mediated cleavage. 45 In addition, the subcellular localization of livin may determine the balance between its anti-and proapoptotic activities. 45 However, the role of livin in the regulation of survival and cell death in pediatric ALL remains to be defined in future studies.
Smac/DIABLO in hematological malignancies
Analysis of Smac/DIABLO expression in non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma tumors by immunohistochemistry revealed that Smac/DIABLO is expressed in most NHL and all Hodgkin's lymphoma cell lines and in 47% primary Hodgkin's lymphoma; however, its expression levels varied among NHL, with 29-68% of tumors being positive. 109 Whether or not expression of Smac/DIABLO bears prognostic impact in these malignancies remains to be addressed in future studies.
XAF1 in hematological malignancies
XAF1 expression is partly or completely lost in many human cancers because of genetic or epigenetic events. 62 The XAF1 gene is located on chromosome 17p13.2, a region that is telomeric to the p53 gene and that is frequently affected by either mutation or loss of heterocygeoucity in malignant cells, suggesting that XAF1 acts as a tumor suppressor gene. 110 Besides this mutational inactivation, epigenetic silencing by promoter hypermethylation of the XAF1 gene has also been identified in several types of solid tumors, including melanoma, gastric, pancreatic and colon carcinoma cancer. [111] [112] [113] A recent study on XAF1 expression in acute leukemia revealed that XAF1 mRNA levels in newly diagnosed acute leukemia patients were significantly lower than that in normal controls. 114 In addition, higher expression levels of XAF1 correlated with a higher complete remission rate. 114 Gene expression profiling unraveled differential expression of the XAF1 and NAIP genes in cancer cells derived from patients with CLL compared with multiple myeloma. 115 However, relatively little is yet known about the role of XAF1 in hematological malignancies compared with solid tumors. For example, whether or not the XAF1 gene is affected by promoter hypermethylation also in leukemia and lymphoma remains to be explored in future studies.
Strategies to target IAPs in hematological malignancies
Smac mimetics
The surface groove of the BIR3 domain of XIAP, which binds endogenous Smac after it is released from mitochondria into the cytosol in the course of apoptosis, has been the focus of many efforts to rationally design small molecules to antagonize XIAP on the basis of the three-dimensional structure of Smac in complex with the BIR3 domain of XIAP. 69, 70, [116] [117] [118] [119] To facilitate the intracellular delivery of Smac mimetic peptides, they were also linked with a carrier molecule, for example, a polyarginine stretch, the Drosophila antennapaedia penetratin sequence and the protein transduction motif of the Tat protein of human immunodeficiency virus. [120] [121] [122] Smac mimetics were reported to either directly trigger apoptotic cell death in leukemia, lymphoma or multiple myeloma cells or to sensitize these cells for apoptosis in response to death-receptor ligation, anticancer drugs or cytolytic T-cell attack. [123] [124] [125] [126] [127] In line with the notion that the endogenous Smac protein can induce ubiquitination and proteasomal degradation of cIAP1 and cIAP2, 128 small-molecule IAP inhibitors that were designed on the basis of the N terminus of Smac were recently reported to stimulate ubiquitination and degradation of cIAP1 and cIAP2 through the proteasome, presumably through activation of the E3 ligase activity of cIAPs. [65] [66] [67] [68] Furthermore, the proapoptotic activity of IAP inhibitors was shown to depend on autocrine tumor necrosis factor-a signaling in cancer cells that are susceptible to these inhibitors as single agents, as inhibition of tumor necrosis factor-a also conferred protection toward IAP inhibitors. [65] [66] [67] [68] In multiple myeloma, the Smac mimetics LBW242 was described to cause apoptosis in cell lines and also in purified patient multiple myeloma cells, including those that were resistant to conventional therapies or the proteasome inhibitor bortezomib. 124 In addition, LBW242 was able to bypass multiple myeloma resistance imposed by interleukin-6 or insulin-like growth factor-1 or by adherence to bone marrow stromal cells, indicating that LBW242 may overcome some types of resistance mediated by the local microenvironment. 124 Furthermore, LBW242 cooperated in combination studies with several agents, including the death receptor ligand TRAIL, proteasome inhibitors, such as bortezomib and NPI-0052, as well as melphalan. 124 In contrast, no significant cytotoxicity of LBW242 was observed against normal lymphocytes or bone marrow stromal cells, pointing to a therapeutic window. This notion was supported also by in vivo data in a multiple myeloma xenograft mouse model, where LBW242 suppressed tumor growth and prolonged survival without considerable toxicities. 124 In AML, the Smac mimetics LBW242 was reported to potentiate the antileukemic activity of the protein tyrosine kinase inhibitor PKC412 on PKC412-sensitive AML cells with mutant FLT3 and was also effective on PKC412-resistant cells. 129 Furthermore, the addition of LBW242 overcame resistance to PKC412 that was mediated by microenvironmental factors, such as the stroma compartment. 129 In vivo, the combination of LBW242 and PKC412 was superior over either agent alone to reduce tumor burden. 129 Also, LBW242 acted in concert with some conventional cytotoxic agents, such as doxorubicin and cytarabine, on AML cells expressing mutant FLT3. 129 A structure-based in silico screening of a traditional herbal medicine three-dimensional structure database identified the natural product embelin as an inhibitor of the BIR3 domain of XIAP. 130 Embelin is derived from the Japanese Ardisia herb and is a cell-permeable, nonpeptidic small-molecular weight compound. 130 Embelin was shown to induce apoptosis and to overcome the protective effect of XIAP in Jurkat T-cell leukemia cells with ectopic expression of XIAP through binding to the BIR3 domain of XIAP. 130 
XIAP BIR2 inhibitors
Moreover, small-molecule inhibitors were developed that selectively disrupt the interaction of the BIR2 domain of XIAP with caspase-3. To this end, screening of a polyphenylurea library using a caspase derepression assay resulted in the identification of nonpeptidic XIAP antagonists that bind to XIAP BIR2. 71, 131 These XIAP antagonists induced apoptosis in AML cell lines as well as in primary patient samples at low micromolar concentrations. 132 It is interesting to note that they caused apoptosis in leukemia cells without the requirement of an additional cytotoxic stimulus and also killed AML cells with high Bcl-2 expression levels consistent with a mode of action that involved derepression of downstream effector caspases. 71, 132 In contrast, polyphenylurea-based XIAP antagonists were not lethal to normal hematopoietic cells in short-term cytotoxicity assays. 132 Furthermore, XIAP BIR2 antagonists were reported to restore caspase-9-mediated apoptosis in both chemotherapy-refractory and -responsive diffuse large B-cell lymphoma cells, whereas they demonstrated no cytotoxicity on peripheral blood mononuclear cells or tonsil germinal-center B cells from healthy donors. 133 Sensitivity to XIAP antagonists was associated with high expression levels of XIAP, low expression levels of Bcl-2 and constitutive caspase-9 activation, 133 indicating that it might be possible to identify patients who most likely benefit from treatment with XIAP antagonists. Moreover, XIAP BIR2 antagonists were shown to enhance CD95-mediated apoptosis in CD40-activated CLL cells, indicating that XIAP inhibitors might enhance the effectiveness of immune-based treatment strategies that target CD40. 134 
XIAP antisense oligonucleotides
At present, antisense oligonucleotides are the most advanced approach to neutralize aberrant expression of XIAP in human cancers. 72 Preclinical studies in leukemia cell lines demonstrated the antileukemic effects of XIAP antisense oligonucleotides, both as single agents and in combination with anticancer drugs, that is, cytarabine and doxorubicin. 135, 136 In animal models, a second-generation, mixed backbone antisense oligonucleotide directed against human XIAP, that is, AEG35156, caused reduction of XIAP mRNA and protein levels at therapeutically feasible doses, which correlated with antitumor activity of XIAP antisense oligonucleotides. 72, 137, 138 Several phase I/II clinical trials using XIAP antisense oligonucleotides as single agents or in combination with chemotherapy, that is, docetaxel, cytarabine and idarubicin, are at present under way in solid tumors as well as in hematological malignancies, for example, in AML and NHL. 138, 139 In a phase I clinical trial, XIAP antisense AEG35156 administered as a continuous intravenous infusion was described to cause a marked, although short-lived, decrease in peripheral lymphoblasts during administration of XIAP antisense that correlated with suppression of XIAP mRNA levels in a patient with NHL. 139 
Inhibition of survivin
Several strategies have also been developed to interfere with survivin expression in human cancer. As far as hematological malignancies are concerned, suppression of survivin levels by antisense oligonucleotides was described to result in growth inhibition of established NHL in a xenograft model. 140 Several phase II clinical trials using a survivin antisense molecule, that is, LY2813008, are ongoing at present. 47 Furthermore, survivin expression can be antagonized by transcriptional repressors, such as YM155 and EM-1421, 73, 74 which are now under evaluation in phase I clinical trials. 47, 141 In addition, small-molecule inhibitors of signal transduction pathways that control survivin expression, for example, antagonists of signal transducer and activator of transcription 3, CDK1 or HSP90, provide alternative strategies to suppress survivin levels in human cancers. 47 
Conclusion
Abnormal expression or function of IAPs and their antagonists may disturb the homeostasis within the lympho-hemotopoietic compartment and may promote the development and progression of leukemia and lymphoma as well as drug resistance. Owing to their overexpression in malignant compared with normal cells, therapeutic targeting of IAPs, for example, by small-molecule inhibitors or antisense oligonucleotides, presents a promising approach for cancer cell-selective induction of apoptosis. Some of these strategies have already entered the clinical stage and are tested at present in (early) clinical trials, including studies in hematological malignancies. For the future clinical development of IAPs targeting cancer therapeutics, it will be pivotal to identify and evaluate molecular markers for patients' selection and monitoring. Another important avenue of research will be to explore whether pan-IAP or more selective IAP inhibitors are better suited for cancer cell-selective induction of cell death. The translation of basic knowledge on IAPs and their antagonists into clinical application is expected to yield novel prognostic markers and cancer therapeutics for patients with hematological malignancies.
